CA
NZ
UK
AU
IND
US
Editas Medicine, Inc. (NASDAQ:EDIT), a gene editing company built around CRISPR technology, received regulatory and ethics approval in Australia to begin its first-in-human Strive trial of EDIT-401, an experimental in vivo gene editing treatment designed to lower LDL cholesterol in patients with a genetic …
Glaukos Corporation (NYSE:GKOS), an ophthalmic medical technology company known for its glaucoma and corneal disease treatments, announced an exclusive license agreement with RevOpsis Therapeutics for RO-104, a first-in-class tri-specific biologic designed to treat several retinal diseases including age-related macular degeneration and diabetic macular edema. …
Medicus Pharma Ltd. (NASDAQ:MDCX), a Canadian-led, precision oncology-focused biotech, issued aShareholderupdate marking its third anniversary as a public company. The update highlighted progress across its three lead assets: CD228V, an antibody-drug conjugate for melanoma and other solid tumors developed using Pfizer's linker-payload platform; SkinJect, …
Myriad Genetics, Inc. (NASDAQ:MYGN), a molecular diagnostics and precision medicine company, announced a collaboration with SOPHiA GENETICS and AstraZeneca to advance a new prostate cancer-specific genomic instability score, called PrGIS. The biomarker builds on the company's existing MyChoice companion diagnostic test, currently used in …
Nexalin Technology, Inc. (NASDAQ:NXL), a Texas-based medical device company developing non-invasive brain stimulation therapies for mental health conditions, said it received written confirmation fromNasdaqthat it regained compliance with the exchange's minimum bid price rule, after its stock closed above $1.00 for 21 consecutive trading …
Pacira BioSciences, Inc. (NASDAQ:PCRX), a specialty pharmaceutical company focused on non-opioid pain management, agreed to be acquired by Viatris for $36.50 per share in cash. The deal, to be carried out through a tender offer followed by a merger, values the company at approximately …
Scholar Rock Holding Corporation (NASDAQ:SRRK), a Massachusetts-based biopharmaceutical company focused on muscle-related diseases, resubmitted itsMarketingapplication to European regulators for apitegromab, a spinal muscular atrophy treatment already approved in the United States under theBrandISEMBYLD. The resubmission swaps in an alternate manufacturing facility after the company …
SOPHiA GENETICS S.A. (NASDAQ:SOPH), a Swiss healthcare technology company known for its genomic data analysis platform, announced a collaboration with Myriad Genetics and AstraZeneca to advance a new prostate cancer-specific genomic instability score, called PrGIS. The biomarker is designed to assess chromosomal instability linked …
Sunshine Biopharma, Inc. (NASDAQ:SBFM), a Florida-based pharmaceutical company developing oncology and antiviral treatments alongside a portfolio of generic drugs, priced a public offering of roughly 10.9 million units at $0.55 per unit, expected to raise about $6.0 million before fees. Each unit includes one …
Viatris Inc. (NASDAQ:VTRS), a global healthcare company formed in 2020 through theMergerof Mylan and Pfizer's Upjohn division, agreed to acquire Pacira BioSciences for $36.50 per share in cash, valuing the deal at approximately $1.65 billion. TheAcquisitionwill be carried out through a tender offer followed …
Please wait processing your request...